Scientific Strategy

There are many ongoing clinical trials using vaccines for Alzheimer’s Disease. Thus far, these vaccines have not been successful largely because of the difficulty in producing high titers of therapeutic antibodies in humans (as opposed to mice). Capo is working to overcome this obstacle by combining three elements:

• Strong Multi-TEP platform;
• Novel proprietary adjuvant (“Advax”); and
• Aβ immunogen.

With this patent pending technique and protocol, we believe it’s possible to achieve titers of therapeutic antibodies 1000x higher than our current competitors. Additionally, we expect to be able to use this cocktail for Parkinson’s Disease.